In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bowman Cox

Executive Editor

Washington, DC
Bowman Cox leads the Pink Sheet's coverage of pharmaceutical manufacturing quality issues. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to drug manufacturers and their quality organizations.

Latest From Bowman Cox

McKesson Tapped For COVID-19 Vaccine Kits To Meet 1 October Distribution Goal

US HHS turns to COVID-19 vaccine distributor to assemble vaccine administration kits, citing revised vaccine delivery schedule.

Coronavirus COVID-19 Distribution

Continuous Manufacturing Centers Of Excellence Measure Resurfaces In US House

Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.

Manufacturing Legislation

COVID-19 Shows US FDA Why It Needs To Know Supply Chain’s Current And Surge Capacities

Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.

Manufacturing Distribution

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

Manufacturing Policy

US FDA Assesses Over 500 Biopharma Plants Remotely Via Records Review; Refines Process

Agency may share outcomes of remote record reviews in lieu of inspections at US and foreign facilities.

Quality Compliance

WHO Proposes Reference Standard For Adventitious Virus Detection

Emerging global standard could speed testing of biologics and gene therapies for stray viral particles, while sparing laboratory animals.

Biologics Gene Therapy
See All
UsernamePublicRestriction

Register